iShares Edge MSCI Europe Quality Factor UCITS ETF EUR (Acc) EUR is a equity ETF from iShares tracking the Edge MSCI Europe Quality Factor index through physical replication. Domiciled in Ireland and launched in 2015, the fund manages about 650 M € and charges a TER of 0.25% — 25 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
iShares Edge MSCI Europe Quality Factor UCITS ETF EUR (Acc) EUR competes with 1 other products on the same index (Edge MSCI Europe Quality Factor): it ranks 1st by fund size and 1st by ongoing cost, with a TER of 0.25% against a group median of 0.25%. It has been listed since 2015, 11 years of track record.
On a €10,000 investment the TER costs 25 € a year, and no product in the group costs less.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 39.8% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Ireland, which determines the tax treatment of income received by the fund and the supervisory authority.
| ASML Holding N.V. | 10.0% |
| ABB Ltd | 4.5% |
| Allianz SE VNA O.N. | 4.4% |
| Rolls-Royce Holdings PLC | 3.3% |
| Nestle S.A. | 3.2% |
| Novartis AG | 3.1% |
| Zurich Insurance Group AG | 3.0% |
| AstraZeneca PLC | 3.0% |
| Roche Holding AG | 2.8% |
| Unilever PLC | 2.5% |
| Borsa Italiana | IEQU | EUR |
| XETRA | CEMQ | EUR |
| Francoforte | CEMQ | EUR |
| London Stock Exchange | IEFQ | GBX |
| SIX Swiss Exchange | IEQU | EUR |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.